BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed
Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August - PG&E (NYSE:PCG), BioMarin P
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Roblox
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - BioMarin Pharmaceu